The U.S. Food and Drug Administration (FDA) has officially authorized LumiThera’s Valeda Light Delivery System for the treatment of dry age-related macular degeneration (AMD), marking a significant advancement in therapeutic options for patients experiencing vision loss due to this condition. The Valeda system is reported to enhance best corrected visual acuity (BCVA) by over five...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here